Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer
Abstract Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer deaths worldwide. Besides common therapeutic approaches, such as surgery, chemotherapy, and radiotherapy, novel therapeutic approaches, including immunotherapy, have been an advent in CRC treatmen...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-02-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-021-01763-9 |
| _version_ | 1818451510058549248 |
|---|---|
| author | Ke-Tao Jin Bo Chen Yu-Yao Liu H uan-Rong Lan Jie-Ping Yan |
| author_facet | Ke-Tao Jin Bo Chen Yu-Yao Liu H uan-Rong Lan Jie-Ping Yan |
| author_sort | Ke-Tao Jin |
| collection | DOAJ |
| description | Abstract Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer deaths worldwide. Besides common therapeutic approaches, such as surgery, chemotherapy, and radiotherapy, novel therapeutic approaches, including immunotherapy, have been an advent in CRC treatment. The immunotherapy approaches try to elicit patients` immune responses against tumor cells to eradicate the tumor. Monoclonal antibodies (mAbs) and chimeric antigen receptor (CAR) T cells are two branches of cancer immunotherapy. MAbs demonstrate the great ability to completely recognize cancer cell-surface receptors and blockade proliferative or inhibitory pathways. On the other hand, T cell activation by genetically engineered CAR receptor via the TCR/CD3 and costimulatory domains can induce potent immune responses against specific tumor-associated antigens (TAAs). Both of these approaches have beneficial anti-tumor effects on CRC. Herein, we review the different mAbs against various pathways and their applications in clinical trials, the different types of CAR-T cells, various specific CAR-T cells against TAAs, and their clinical use in CRC treatment. |
| first_indexed | 2024-12-14T21:08:20Z |
| format | Article |
| id | doaj.art-479eaa31706a495d807405bd2b98021a |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-12-14T21:08:20Z |
| publishDate | 2021-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-479eaa31706a495d807405bd2b98021a2022-12-21T22:47:20ZengBMCCancer Cell International1475-28672021-02-0121111510.1186/s12935-021-01763-9Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancerKe-Tao Jin0Bo Chen1Yu-Yao Liu2H uan-Rong Lan3Jie-Ping Yan4Department of Colorectal Surgery, Affiliated Jinhua Hosptial, Zhejiang University School of MedicineDepartment of Neurology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeDepartment of Colorectal Surgery, Affiliated Jinhua Hosptial, Zhejiang University School of MedicineDepartment of Breast and Thyroid Surgery, Affiliated Jinhua Hosptial, Zhejiang University School of MedicineDepartment of Pharmacy, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical CollegeAbstract Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer deaths worldwide. Besides common therapeutic approaches, such as surgery, chemotherapy, and radiotherapy, novel therapeutic approaches, including immunotherapy, have been an advent in CRC treatment. The immunotherapy approaches try to elicit patients` immune responses against tumor cells to eradicate the tumor. Monoclonal antibodies (mAbs) and chimeric antigen receptor (CAR) T cells are two branches of cancer immunotherapy. MAbs demonstrate the great ability to completely recognize cancer cell-surface receptors and blockade proliferative or inhibitory pathways. On the other hand, T cell activation by genetically engineered CAR receptor via the TCR/CD3 and costimulatory domains can induce potent immune responses against specific tumor-associated antigens (TAAs). Both of these approaches have beneficial anti-tumor effects on CRC. Herein, we review the different mAbs against various pathways and their applications in clinical trials, the different types of CAR-T cells, various specific CAR-T cells against TAAs, and their clinical use in CRC treatment.https://doi.org/10.1186/s12935-021-01763-9Colorectal cancerImmunotherapyMonoclonal antibodyChimeric antigen receptor (CAR) T cells |
| spellingShingle | Ke-Tao Jin Bo Chen Yu-Yao Liu H uan-Rong Lan Jie-Ping Yan Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer Cancer Cell International Colorectal cancer Immunotherapy Monoclonal antibody Chimeric antigen receptor (CAR) T cells |
| title | Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer |
| title_full | Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer |
| title_fullStr | Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer |
| title_full_unstemmed | Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer |
| title_short | Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer |
| title_sort | monoclonal antibodies and chimeric antigen receptor car t cells in the treatment of colorectal cancer |
| topic | Colorectal cancer Immunotherapy Monoclonal antibody Chimeric antigen receptor (CAR) T cells |
| url | https://doi.org/10.1186/s12935-021-01763-9 |
| work_keys_str_mv | AT ketaojin monoclonalantibodiesandchimericantigenreceptorcartcellsinthetreatmentofcolorectalcancer AT bochen monoclonalantibodiesandchimericantigenreceptorcartcellsinthetreatmentofcolorectalcancer AT yuyaoliu monoclonalantibodiesandchimericantigenreceptorcartcellsinthetreatmentofcolorectalcancer AT huanronglan monoclonalantibodiesandchimericantigenreceptorcartcellsinthetreatmentofcolorectalcancer AT jiepingyan monoclonalantibodiesandchimericantigenreceptorcartcellsinthetreatmentofcolorectalcancer |